Skip to main content
. 2017 Aug 10;8(43):74378–74390. doi: 10.18632/oncotarget.20102

Figure 6. ELISA showed the presence of IgG anti-SP17 in 10/22 BC patients (∼45%) and in 5/6 TNBC patients.

Figure 6

The right-sided reference interval (OD=0.17, dotted line) was calculated in accordance to the Clinical and Laboratory Standards Institute’s (CLSI) guidelines [64], using MedCalc software. *, one-way ANOVA and Dunn's multiple comparisons test p<0.05.